What is the official website of LGC Mikromol™ ?

The official website of LGC Mikromol™ is https://www.lgcstandards.com/mikromol.

What is LGC Mikromol™'s cybersecurity risk score?

LGC Mikromol™ has an AI-generated cybersecurity risk score of 754 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has LGC Mikromol™ experienced?

According to Rankiteo, LGC Mikromol™ currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has LGC Mikromol™ been affected by any supply chain cyber incidents ?

According to Rankiteo, LGC Mikromol™ has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does LGC Mikromol™ have SOC 2 Type 1 certification ?

According to Rankiteo, LGC Mikromol™ is not certified under SOC 2 Type 1.

Does LGC Mikromol™ have SOC 2 Type 2 certification ?

According to Rankiteo, LGC Mikromol™ does not hold a SOC 2 Type 2 certification.

Does LGC Mikromol™ comply with GDPR ?

According to Rankiteo, LGC Mikromol™ is not listed as GDPR compliant.

Does LGC Mikromol™ have PCI DSS certification ?

According to Rankiteo, LGC Mikromol™ does not currently maintain PCI DSS compliance.

Does LGC Mikromol™ comply with HIPAA ?

According to Rankiteo, LGC Mikromol™ is not compliant with HIPAA regulations.

Does LGC Mikromol™ have ISO 27001 certification ?

According to Rankiteo,LGC Mikromol™ is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does LGC Mikromol™ operate in ?

LGC Mikromol™ operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does LGC Mikromol™ have ?

LGC Mikromol™ employs approximately None employees people worldwide.

Does LGC Mikromol™ own any subsidiaries ?

LGC Mikromol™ presently has no subsidiaries across any sectors.

How many LinkedIn followers does LGC Mikromol™ have ?

LGC Mikromol™'s official LinkedIn profile has approximately 3,322 followers.

What is the NAICS classification code for LGC Mikromol™ ?

LGC Mikromol™ is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does LGC Mikromol™ have a Crunchbase profile ?

No, LGC Mikromol™ does not have a profile on Crunchbase.

Does LGC Mikromol™ have a LinkedIn profile ?

Yes, LGC Mikromol™ maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/lgc-mikromol.

How many cybersecurity incidents has LGC Mikromol™ experienced ?

As of September 13, 2026, Rankiteo reports that LGC Mikromol™ has not experienced any cybersecurity incidents.

How many peer or competitor companies does LGC Mikromol™ have ?

LGC Mikromol™ has an estimated 5,760 peer or competitor companies worldwide.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

LGC Mikromol™

Boost Score +25 with badge (5 left)

754

/1000

Fair

779

/1000

Fair

LGC Mikromol™ Vendor Cyber Rating & Cyber Score

lgcstandards.com

Add Your Compliance Badge

At Mikromol we combine an incomparable depth of pharmaceutical knowledge with 25 years of manufacturing experience and scientific acumen to ensure our portfolio of over 5,000 Impurity, Active Pharmaceutical Ingredient (API) and Excipient reference standards is of the highest quality. We go beyond the standard, supporting you with the highest accreditation for reference standard purity and a comprehensive Certificate of Analysis, to help you achieve greater analytical certainty. Mikromol: making a positive, measurable difference.

LGC Mikromol™

LGC Mikromol™ CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

LGC Mikromol™ Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for LGC Mikromol™

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for LGC Mikromol™ in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for LGC Mikromol™ in 2026.

Incident Types LGC Mikromol™ vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for LGC Mikromol™ in 2026.

Incident History - LGC Mikromol™ (X = Date, Y = Severity)

Loading…

SUBSIDIARY

LGC Mikromol™ Subsidiaries

LGC Mikromol™

Pharmaceutical Manufacturing

Website: https://www.lgcstandards.com/mikromol

Company Size: None employees

LGCBiotechnology Research

LGC Biosearch TechnologiesBiotechnology

LGC ASSUREPublic Safety

UK National Measurement Laboratory (NML) at LGCResearch Services

LGC AXIO Proficiency TestingChemical Manufacturing

LGC IndustrialChemical Manufacturing

LGC in partnership with ATCCBiotechnology Research

LGC LoGiCalChemical Manufacturing

Loading…

LGC Mikromol™ Similar Companies

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Loading…

NEWS

LGC Mikromol™ CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-90647

SUMMARY

ASE/Kalkitech ASE2000 V2 Communication Test Set 2.35 through 2.37 on Windows contains an improper certificate validation vulnerability in the IEC 60870-5-104 TLS client (Task Mode). This allows a network-positioned attacker to bypass certificate validation via a certificate with multiple simultaneous faults, enabling a Man-in-the-Middle attack on protected communications.

Published

Date2026-09-12

Updated

Date2026-09-12

RISK INFORMATION (Score: 7.4)

cvss3

Base Score: 7.4

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:H/A:N

cvss4

Base Score: 9.1

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:N/PR:N/UI:N/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.2

Exploitability

2.2

REFERENCES

https://www.ase-systems.com/wp-content/uploads/2026/07/CYB_2026_86278_Advisory_v1.0.pdf

CVE-2026-90487

SUMMARY

A vulnerability was found in Xuxueli xxl-job up to 3.4.2. Affected by this issue is some unknown functionality of the file xxl-job-admin/src/main/java/com/xxl/job/admin/business/controller/JobGroupController.java. The manipulation results in improper privilege management. The attack may be launched remotely. The exploit has been made public and could be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-09-12

Updated

Date2026-09-12

RISK INFORMATION (Score: 4.3)

cvss2

Base Score: 4.0

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:N/A:N

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.8

REFERENCES

CVE-2026-90486

SUMMARY

A vulnerability has been found in openstatusHQ openstatus up to f04c827112f30a11d571ebdad3892826034d6265. Affected by this vulnerability is an unknown functionality of the file apps/status-page/src/lib/proxy/resolve-custom-domain-rewrite.ts. The manipulation leads to server-side request forgery. The attack may be initiated remotely. This product uses a rolling release model to deliver continuous updates. As a result, specific version information for affected or updated releases is not available. The identifier of the patch is 86f370c9c20074c3c3fdec53a359874b8e670fd4. It is suggested to install a patch to address this issue. This issue got fixed with a silent patch.

Published

Date2026-09-12

Updated

Date2026-09-12

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-79300

SUMMARY

SEP sesam before 5.2.0.24 mishandles User Authorization with MFA. If AD authentication is configured and MFA is enforced, an attacker can create a second OTP access capability. SEP sesam and Active Directory handle username capitalization differently, which may allow multiple SEP sesam user accounts to be created for the same Active Directory (AD) account. Active Directory treats usernames as case-insensitive, while SEP sesam distinguishes between different letter casing. As a result, the same AD user can be represented by multiple SEP sesam user accounts that differ only in username capitalization. When Active Directory authentication is configured and multi-factor authentication (MFA) is enforced, this behavior may allow an additional OTP Authenticator to be registered for the same AD account, reducing the effectiveness of MFA protection.

Published

Date2026-09-12

Updated

Date2026-09-12

RISK INFORMATION (Score: 3.5)

cvss3

Base Score: 3.5

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:C/C:N/I:L/A:N

Impact Score

1.4

Exploitability

1.8

REFERENCES

https://wiki.sep.de/wiki/index.php/Release_Notes_5.2.0_Artemis#fixed

CVE-2026-90485

SUMMARY

A flaw has been found in IOBit Uninstaller 15.5.0.11. Affected by this issue is the function sub_11838 of the file IURegistryFilter.sys of the component IOCTL Dispatch Handler. This manipulation causes null pointer dereference. The attack requires local access. The exploit has been published and may be used. Identical IURegistryFilter.sys ships across multiple IObit families. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-09-12

Updated

Date2026-09-12

RISK INFORMATION (Score: 5.5)

cvss2

Base Score: 4.6

Complexity: LOW

AV:L/AC:L/Au:S/C:N/I:N/A:C

cvss3

Base Score: 5.5

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

cvss4

Base Score: 5.4

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

1.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

LGC Mikromol™ Vendor Cyber Rating & Cyber Score

LGC Mikromol™ A.I CyberSecurity Scoring

LGC Mikromol™ CyberSecurity News & History

LGC Mikromol™ Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for LGC Mikromol™

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types LGC Mikromol™ vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - LGC Mikromol™ (X = Date, Y = Severity)

LGC Mikromol™ Subsidiaries

LGC Mikromol™

LGC Mikromol™ Similar Companies

AbbVie

Parexel

Sandoz

Eli Lilly and Company

Astellas Pharma

Lupin

MSD

MANKIND PHARMA LTD

AUROBINDO PHARMA LTD

LGC Mikromol™ CyberSecurity News

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

LGC Mikromol™ CyberSecurity News & History

LGC Mikromol™ Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for LGC Mikromol™

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types LGC Mikromol™ vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - LGC Mikromol™ (X = Date, Y = Severity)

LGC Mikromol™ Subsidiaries

LGC Mikromol™

LGC Mikromol™ Similar Companies

AbbVie

Parexel

Sandoz

Eli Lilly and Company

Astellas Pharma

Lupin

MSD

MANKIND PHARMA LTD

AUROBINDO PHARMA LTD

LGC Mikromol™ CyberSecurity News

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo